82
Participants
Start Date
December 22, 2014
Primary Completion Date
October 3, 2017
Study Completion Date
October 3, 2017
SYN120
SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
Placebo
Placebo QD
Parkinson's Disease Movement Disorder Center, Philadelphia
Thomas Jefferson University, Philadelphia
Department of Neurology, University of Maryland Parkinson's Disease & Movement Disorder Center, Baltimore
Wake Forest Baptist Health Sciences, Winston-Salem
Duke University, Durham
Medical University of South Carolina, Charleston
Augusta University, Augusta
Parkinson's Disease & Movement Disorder Center of Boca Raton, Boca Raton
The University of Alabama at Birmingham, Birmingham
University of Iowa, Carver College of Medicine, Iowa City
Struthers Parkinson's Center, Golden Valley
Northwestern University, Feinberg School of Medicine, Chicago
Rush University Medical Center, Chicago
Parkinson's Disease & Movement Disorder Center, University of Kansas Medical Center, Kansas City
Baylor Univeristy, Houston
Houston Methodist Neurological Institute/Movement Disorders Clinic, Houston
Banner Sun Health Research Institute, Sun City
UC San Diego, La Jolla
Massachusetts General Hospital, Boston
Atlantic Neuroscience Institute, Summit
Lead Sponsor
Collaborators (1)
Michael J. Fox Foundation for Parkinson's Research
OTHER
Massachusetts General Hospital
OTHER
Acorda Therapeutics
INDUSTRY
Biotie Therapies Inc.
INDUSTRY